Your browser doesn't support javascript.
loading
Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting.
Sprecher, Armand; Cross, Robert; Marzi, Andrea; Martins, Karen A; Wolfe, Daniel; Montgomery, Joel M; Spiropoulou, Christina F; Cihlar, Tomas; Ahuka-Mundeke, Steve; Nyhuis, Tara; Teicher, Carrie; Crozier, Ian; Strong, Jim; Kobinger, Gary; Woolsey, Courtney; Geisbert, Thomas W; Feldmann, Heinz; Muyembe, Jean-Jacques.
Afiliação
  • Sprecher A; Médecins Sans Frontières, Brussels, Belgium.
  • Cross R; Galveston National Laboratory, University of Texas Medical Branch, Galveston.
  • Marzi A; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
  • Martins KA; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, US Department of Health and Human Services, Washington, District of Columbia.
  • Wolfe D; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, US Department of Health and Human Services, Washington, District of Columbia.
  • Montgomery JM; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Spiropoulou CF; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Cihlar T; Gilead Sciences Inc, Foster City, California.
  • Ahuka-Mundeke S; Institut National de Recherche Biomédicale, Kinshasa, Republic of the Congo.
  • Nyhuis T; Kinshasa Teaching Hospital, School of Medicine, Kinshasa University, Democratic Republic of the Congo.
  • Teicher C; Mapp Biopharmaceutical, Inc, San Diego, California.
  • Crozier I; Médecins Sans Frontières, New York, New York.
  • Strong J; Clinical Monitoring Program Research Directorate, Frederick National Laboratory for Cancer Research, Maryland.
  • Kobinger G; Special Pathogens Program, National Microbiology Laboratory Branch, Public Health Agency of Canada.
  • Woolsey C; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg.
  • Geisbert TW; Department of Pediatrics and Child Health, University of Manitoba, Winnipeg.
  • Feldmann H; Galveston National Laboratory, University of Texas Medical Branch, Galveston.
  • Muyembe JJ; Galveston National Laboratory, University of Texas Medical Branch, Galveston.
J Infect Dis ; 228(Suppl 7): S474-S478, 2023 11 13.
Article em En | MEDLINE | ID: mdl-37596837
ABSTRACT
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Filoviridae / Infecções por Filoviridae / Doença pelo Vírus Ebola / Ebolavirus Tipo de estudo: Guideline Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Filoviridae / Infecções por Filoviridae / Doença pelo Vírus Ebola / Ebolavirus Tipo de estudo: Guideline Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2023 Tipo de documento: Article